Retatrutide (LY3437943): Multi-Receptor Agonism at GIP, GLP-1 and Glucagon Receptors

Retatrutide is a synthetic linear 39-amino acid peptide derived structurally from native human GIP (glucose-dependent insulinotropic polypeptide), carrying targeted substitutions engineered to impart high-affinity recognition for GLP-1 and glucagon receptors while preserving enzymatic resistance against dipeptidyl peptidase-4 (DPP-4). The exact primary sequence is: Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Lys({AEEA}2-gamma-Glu-C20-diacid)-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.

The N-terminal region features an alpha-aminoisobutyric acid (Aib) residue at position 2, sterically preventing DPP-4 cleavage at the Tyr1-Aib2 peptide bond. A hydrophilic spacer composed of two 2-(2-(2-aminoethoxy)ethoxy)acetic acid (AEEA) units coupled to an L-gamma-glutamic acid is attached to the epsilon-amino group of Lys17, which anchors a 20-carbon dicarboxylic fatty acid (eicosanedioic acid). This lipophilic C20 diacid tail binds reversibly to the hydrophobic clefts of circulating serum albumin, creating an endogenous intravascular depot that reduces glomerular filtration and extends the plasma elimination half-life to approximately 6 days in humans.

Far-UV circular dichroism (CD) spectra confirm that retatrutide adopts a defined alpha-helical conformation between residues 7 and 28 in physiological buffers, mimicking the receptor-bound states of native incretins while presenting a trifunctional pharmacophore capable of productive docking with class B secretin-like G-protein coupled receptors.

In cell lines expressing human recombinant receptors, retatrutide demonstrates potent, balanced triple-receptor occupancy. Radioligand displacement and functional cyclic AMP (cAMP) generation assays demonstrate EC50 values of 0.077 ± 0.012 nM for human GIPR, 0.79 ± 0.08 nM for human GLP-1R, and 0.089 ± 0.015 nM for human GCGR. This pharmacodynamic profile provides equal-affinity co-stimulation of GIPR and GCGR, complemented by nanomolar GLP-1R engagement.

Downstream second-messenger cascades involve coupling through stimulatory G-protein alpha-subunits (Gs-alpha), prompting robust adenylate cyclase activation and sustained accumulation of intracellular cAMP. In pancreatic beta-cells, this leads to protein kinase A (PKA) activation, exchange protein directly activated by cAMP 2 (Epac2) induction, closure of ATP-sensitive K+ (K-ATP) channels, and subsequent glucose-dependent exocytosis of insulin granules.

Crucially, biased signaling profiling reveals that retatrutide exhibits lower efficacy in recruiting beta-arrestin-1 and beta-arrestin-2 to the receptor complex compared to native GLP-1 or glucagon. This attenuation of beta-arrestin recruitment mitigates clathrin-mediated receptor internalization and lysosomal degradation, permitting sustained cell-surface receptor signaling and preventing pharmacological tachyphylaxis during chronic administration.

The therapeutic hallmark distinguishing retatrutide from dual GIP/GLP-1 agonists (such as tirzepatide) is its coordinated engagement of the hepatic glucagon receptor. In primary hepatocyte cultures and diet-induced obese (DIO) murine models, retatrutide stimulates hepatic lipolysis and fatty acid beta-oxidation via transcriptional upregulation of carnitine palmitoyltransferase-1A (CPT-1A) and acyl-CoA oxidase 1 (ACOX1).

Simultaneously, retatrutide elevates resting energy expenditure (REE) by approximately 15–20% in animal calorimetry studies through the induction of uncoupling protein 1 (UCP-1) in brown adipose tissue (BAT) and the browning of subcutaneous white adipose tissue (WAT). This thermogenic expenditure occurs without requiring prolonged adrenergic activation or tachycardia.

Importantly, despite sustained glucagon receptor agonism, baseline euglycemia is rigorously maintained. The potent insulinotropic actions mediated by GIPR and GLP-1R counteract hepatic glycogenolysis and gluconeogenesis, preventing paradoxical glycemic elevation even under high-carbohydrate baseline conditions.

In clinical Phase 1 and Phase 2 trials (Jastreboff et al., NEJM 2023; Rosenstock et al., Lancet 2023), retatrutide demonstrated linear, dose-proportional pharmacokinetics across doses ranging from 0.5 mg to 12 mg administered subcutaneously once weekly. Time to maximum concentration (Tmax) spans 24 to 48 hours post-injection, with a mean terminal elimination half-life of 144 hours (~6.0 days), supporting weekly administration.

In a 48-week double-blind, randomized, placebo-controlled Phase 2 trial involving 338 adults with obesity (BMI ≥30 or ≥27 with weight-related comorbidities), participants randomized to the 12 mg retatrutide dose achieved a mean body weight reduction of 24.2% (-26.2 kg), with 100% of participants achieving ≥5% weight loss, 83% achieving ≥15%, and 26% achieving ≥30% body weight loss. No plateau in weight loss was observed at week 48, suggesting continued lipolytic trajectory with prolonged exposure.

Secondary cardiometabolic endpoints demonstrated dramatic improvements: mean systolic and diastolic blood pressure dropped by 10.3 mmHg and 6.0 mmHg respectively, fasting triglycerides decreased by 40%, and non-alcoholic fatty liver disease (NAFLD) biomarkers indicated complete resolution of hepatic steatosis in over 85% of subjects receiving ≥8 mg doses.

Lyophilized retatrutide is synthesized as a trifluoroacetate (TFA) or acetate salt, appearing as a dense, white, amorphous lyophilized cake in sterile USP Type I borosilicate glass vials. The monoisotopic exact mass is 4731.33 Da, with an average molecular weight of 4734.2 Da.

For analytical reconstitution of a 5.0 mg or 10.0 mg vial, 2.0 mL of Bacteriostatic Water for Injection USP (containing 0.9% w/v benzyl alcohol) is recommended. The diluent should be dispensed gently along the interior glass wall using a sterile 25G–27G needle to avoid mechanical shear stresses. Swirling must be gentle; vortexing or vigorous shaking can induce tertiary unfolding and irreversible aggregate formation. Full dissolution occurs within 60 to 90 seconds, producing an optically clear, non-viscous solution with neutral pH (6.8–7.4).

Solid lyophilized vials maintain biochemical stability when stored at -20°C (desiccated) for up to 36 months, or at 2°C–8°C for 12 months. Upon reconstitution with 0.9% benzyl alcohol, solutions maintain ≥98.5% chromatographic purity when refrigerated at 2°C–8°C for up to 28 days. Repeated freeze-thaw cycles of reconstituted liquid must be avoided due to the risk of ice crystal shear of the C20 diacid side-chain.

The adverse event profile observed in Phase 2 clinical programs is consistent with incretin-class pharmacology, predominantly comprising mild-to-moderate, transient gastrointestinal events: nausea (42%), diarrhea (31%), vomiting (20%), and constipation (18%). These events are mitigated significantly by gradual monthly dose titration protocols (e.g., initiating at 2.0 mg or 4.0 mg before escalating to 8.0 mg or 12.0 mg).

Transient increases in resting heart rate (mean peak increase of 5–8 beats per minute) were documented, peaking at weeks 16–24 and subsequently declining toward baseline by week 48. Extensive telemetry monitoring revealed no clinically meaningful arrhythmia signals or QT prolongation.

Endocrine feedback axes remain intact; no cases of symptomatic hypoglycemia were reported in non-diabetic populations due to the strictly glucose-dependent nature of GIP and GLP-1 insulinotropic coupling. Pancreatic lipase and amylase elevations were largely asymptomatic, with incidence rates comparable to established GLP-1 mono-agonists.